To investigate whether other agents can enhance SL-CoVs entry and evade IFITMs-mediated restriction, we tested an antibiotic, named amphotericin B (AmphoB), which is commonly used in clinics to treat systemic fungal infections and has been shown to neutralizing IFITM3-mediated restriction of IAV infection [54]. The gene discussed is IFITM3; the disease is fungal infectious disease.